AR037634A1 - Combinacion farmaceutica, una composicion farmaceutica, uso de un agonista del receptor de adenosina a2a y dispositivo de inhalacion - Google Patents
Combinacion farmaceutica, una composicion farmaceutica, uso de un agonista del receptor de adenosina a2a y dispositivo de inhalacionInfo
- Publication number
- AR037634A1 AR037634A1 ARP020104685A ARP020104685A AR037634A1 AR 037634 A1 AR037634 A1 AR 037634A1 AR P020104685 A ARP020104685 A AR P020104685A AR P020104685 A ARP020104685 A AR P020104685A AR 037634 A1 AR037634 A1 AR 037634A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- homopiperidin
- piperidin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 29
- -1 homopiperidin-3-yl Chemical group 0.000 abstract 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 12
- 229910052757 nitrogen Inorganic materials 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 125000002947 alkylene group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 abstract 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 4
- 239000000048 adrenergic agonist Substances 0.000 abstract 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 3
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 abstract 3
- 125000002393 azetidinyl group Chemical group 0.000 abstract 3
- 125000001589 carboacyl group Chemical group 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 3
- 230000000414 obstructive effect Effects 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 abstract 2
- 239000002465 adenosine A2a receptor agonist Substances 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 125000003031 C5-C7 cycloalkylene group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 abstract 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004263 tetrahydroisoquinolin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])C2=C([H])C([H])=C([H])C([H])=C2C1([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una combinación inhalada de (a) un agonista del receptor de adenosina A2a de fórmula (1) o una de sus sales o solvatos farmacéuticamente aceptables, caracterizada porque R1 es H, alquilo C1-6 o fluorenilo, estando dicho alquilo C1-6 opcionalmente sustituido con 1 o 2 sustituyentes seleccionados cada uno independientemente de fenilo y naftilo, estando dichos fenilo y naftilo opcionalmente sustituidos con alquilo C1-6, alcoxi C1-6, halo o ciano; (A) R2 es H o alquilo C1-6, R15 es H o alquilo C1-6 y x es (i) alquileno C2-3 no ramificado, opcionalmente sustituido con alquilo C1-6 o cicloalquilo C3-8, o (ii) un grupo de fórmula -(CH2)n-W-(CH2)p en la que W es cicloalquileno C5-7 opcionalmente sustituido con alquilo C1-6, n es 0 ó 1 y p es 0 ó 1, o (B) R15 es H o alquilo C1-6; y R2 y X, tomados junto al átomo de nitrógeno al que se encuentran unidos, representan azetidin-3-ilo, pirrolidin-3-ilo, piperidin-3-ilo, piperidin-4-ilo, homopiperidin-3-ilo u homopiperidin-4-ilo, estando cada uno opcionalmente sustituido con alquilo C1-6, o (C) R2 es H o alquilo C1-6, y R15 y X, tomados junto al átomo de nitrógeno al que se encuentran unidos, representan azetidin-3-ilo, pirrolidin-3-ilo, piperidin-3-ilo, piperidin-4-ilo, homopiperidin-3-ilo u homopiperidin-4-ilo, estando cada uno opcionalmente sustituido con alquilo C1-6; cualquiera de R3 y R4, tomados junto con el átomo de nitrógeno al que se encuentran unidos, representan azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, homopiperidinilo u homopiperazinilo, estando cada uno opcionalmente sustituido en un átomo de nitrógeno o de carbono de anillo con alquilo C1-6 o cicloalquilo C3-8 y opcionalmente sustituido en un átomo de carbono de anillo no adyacente a un átomo de nitrógeno de anillo con -NR6R7, O, R3 es H, alquilo C1-6, cicloalquilo C3-8 o bencilo y R4 es (a) azetidin-3-ilo, pirrolidin-3-ilo, piperidin-3-ilo, piperidin-4-ilo, homopiperidin-3-ilo u homopiperidin-4-ilo, estando cada uno opcionalmente sustituido con alquilo C1-6, cicloalquilo C3-8, fenilo, bencilo, o het, (b) -(alquileno C2-6)-R8, (c) -(alquileno C1-6)-R13, o (d) alquilo C1-6 o cicloalquilo C3-8; R5 es CH2OH o CONR14R14; cada uno de R6 y R7 representa independientemente H o alquilo C1-6 o, tomados junto con el átomo de nitrógeno al que se encuentran unidos, representan azetidinilo, pirrolidinilo, o piperidinilo, estando dichos azetidinilo, pirrolidinilo o piperidinilo opcionalmente sustituido con alquilo C1-6; R8 es (i) azetidin-1-ilo, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo, piperazin-1-ilo, homopiperidin-1-ilo, homopiperazin-1-ilo o tetrahidroisoquinolin-1-ilo, estando cada uno opcionalmente sustituido sobre un átomo de carbono de anillo con alquilo C1-6, cicloalquilo C3-8, fenilo, (alcoxi C1-6)(alquilo C1-6), R9R9N-(alquilo C1-6), fluoro(alquilo C1-6), -CONR9R9, -COOR9 o alcanoilo C2-5, y opcionalmente sustituido sobre un átomo de carbono de anillo no adyacente a un átomo de nitrógeno de anillo con fluoro(alcoxi C1-6), halo, -OR9, ciano, -S(O)mR10, -NR9R9, -SO2NR9R9, -NR9COR10 o -NR9SO2R10, y estando dichos piperazin-1-ilo y homopiperazin-1-ilo opcionalmente sustituido en el átomo de nitrógeno de anillo no unido al grupo alquileno C2-6 con alquilo C1-6, fenilo, (alcoxi C1-6)(alquilo C2-6), R9R9N-(alquilo C1-6), fluoro(alquilo C1-6), alcanoilo C2-5, -COOR10, cicloalquilo C3-8, -SO2R10, -SO2NR9R9 o -CONR9R9, o (ii) NR11R12; R9 es H, alquilo C1-6, cicloalquilo C3-8 o fenilo; R10 es alquilo C1-6, cicloalquilo C3-8 o fenilo; R11 es H, alquilo C1-6, cicloalquilo C3-8 o bencilo; R12 es H, alquilo C1-6, cicloalquilo C3-8, fenilo, bencilo, fluoro(alquilo C1-6), -CONR9R9, -COOR10, alcanoilo C2-5 o -SO2NR9R9; R13 es (a) fenilo, piridin-2-ilo, piridin-3-ilo o piridin-4-ilo, estando cada uno opcionalmente sustituido con alquilo C1-6, alcoxi C1-6, -(alquileno C1-3)-(alcoxi C1-6), halo, ciano, -(alquileno C1-3)-CN, -CO2H, -(alquileno C1-3)-CO2H, -CO2(alquilo C1-6), -(alquileno C1-3)-CO2-(alquilo C1-6), -(alquileno C1-3)-NR14R14, -CONR14R14 o -(alquileno C1-3)-CONR14R14, o (b) azetidin-2-ilo, azetidin-3-ilo, pirrolidin-2-ilo, pirrolidin-3-ilo, piperidin-2-ilo, piperidin-3-ilo, piperidin-4-ilo, homopiperidin-2-ilo, homopiperidin-3-ilo u homopiperidin-4-ilo, estando cada uno opcionalmente sustituido con alquilo C1-6, cicloalquilo C3-8, fenilo, bencilo o het; R14 es H o alquilo C1-6, opcionalmente sustituido con ciclopropilo; m es 0, 1 o 2; Y es CO, CS, SO2, o C=N(CN), y "het", usado en la definición de R4 y R13, es un anillo de 4 a 6 miembros unido por C, heterociclo que tiene de 1 a 4 heteroátomos de nitrógeno de anillo o 1 o 2 heteroátomos de anillo, nitrogeno y 1 heteroátomo de anillo oxigeno o 1 azufre, opcionalmente sustituido con alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6, cicloalcoxi C3-8, hidroxi, oxo, o halo; y (b) un agonista del receptor b2-adrenérgico. Reivindicación 6: Una combinación según una cualquiera de las reivindicaciones 1 a 4 caracterizada porque es para la administración simultánea, secuencial o por separado en el tratamiento de una enfermedad obstructiva de las vías respiratorias u otra enfermedad inflamatoria. Reivindicación 7: Una composición farmacéutica caracterizada porque comprende un agonista del receptor de adenosina A2a de fórmula (1), según se define en la reivindicación 1, un agonista del receptor b2-adrenérgico y un excipiente, diluyente o vehículo farmacéuticamente aceptable, para administración por vía inhalada en el tratamiento de una enfermedad obstructiva de las vías respiratorias u otra enfermedad inflamatoria. Reivindicación 13: Un dispositivo de inhalación para la administración simultánea, secuencial o por separado de un agonista del receptor de adenosina A2a de fórmula (1), como se define en la reivindicación 1 y un agonista del receptor b2-adrenérgico, caracterizado porque es útil en el tratamiento de una enfermedad obstructiva de las vías respiratorias u otra enfermedad inflamatoria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129270.5A GB0129270D0 (en) | 2001-12-06 | 2001-12-06 | Pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037634A1 true AR037634A1 (es) | 2004-11-17 |
Family
ID=9927164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104685A AR037634A1 (es) | 2001-12-06 | 2002-12-04 | Combinacion farmaceutica, una composicion farmaceutica, uso de un agonista del receptor de adenosina a2a y dispositivo de inhalacion |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP1455799B1 (es) |
| JP (1) | JP2005513041A (es) |
| KR (1) | KR100685557B1 (es) |
| CN (1) | CN1856314A (es) |
| AP (2) | AP2004003082A0 (es) |
| AR (1) | AR037634A1 (es) |
| AT (1) | ATE293982T1 (es) |
| AU (1) | AU2002351066B2 (es) |
| BR (1) | BR0214998A (es) |
| CA (1) | CA2469085A1 (es) |
| CO (1) | CO5580752A2 (es) |
| DE (1) | DE60203934T2 (es) |
| DK (1) | DK1455799T3 (es) |
| EA (1) | EA200400639A1 (es) |
| EC (1) | ECSP045132A (es) |
| ES (1) | ES2239728T3 (es) |
| GB (1) | GB0129270D0 (es) |
| GT (1) | GT200200258A (es) |
| HN (1) | HN2002000348A (es) |
| HR (1) | HRP20040517A2 (es) |
| HU (1) | HUP0402540A3 (es) |
| IS (1) | IS7280A (es) |
| MA (1) | MA27150A1 (es) |
| MX (1) | MXPA04005506A (es) |
| NO (1) | NO20042839L (es) |
| NZ (1) | NZ533054A (es) |
| OA (1) | OA12738A (es) |
| PA (1) | PA8560701A1 (es) |
| PE (1) | PE20030834A1 (es) |
| PL (1) | PL370739A1 (es) |
| PT (1) | PT1455799E (es) |
| SV (1) | SV2004001426A (es) |
| TN (1) | TNSN04101A1 (es) |
| TW (1) | TWI256388B (es) |
| UY (1) | UY27566A1 (es) |
| WO (1) | WO2003047598A1 (es) |
| ZA (1) | ZA200403966B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785969B1 (ko) * | 2004-05-12 | 2007-12-14 | 동아제약주식회사 | Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| AU2013388034B2 (en) | 2013-04-30 | 2019-08-15 | Aspeya US Inc. | Dry powder formulations and methods of use |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| CA3076353A1 (en) | 2017-09-22 | 2019-03-28 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
| JPWO2022050230A1 (es) * | 2020-09-03 | 2022-03-10 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003960D0 (en) * | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| TWI227240B (en) * | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
-
2001
- 2001-12-06 GB GBGB0129270.5A patent/GB0129270D0/en not_active Ceased
-
2002
- 2002-11-28 CN CNA028244168A patent/CN1856314A/zh active Pending
- 2002-11-28 WO PCT/IB2002/005057 patent/WO2003047598A1/en not_active Ceased
- 2002-11-28 AU AU2002351066A patent/AU2002351066B2/en not_active Ceased
- 2002-11-28 EP EP02785778A patent/EP1455799B1/en not_active Expired - Lifetime
- 2002-11-28 JP JP2003548853A patent/JP2005513041A/ja active Pending
- 2002-11-28 HR HR20040517A patent/HRP20040517A2/hr not_active Application Discontinuation
- 2002-11-28 EA EA200400639A patent/EA200400639A1/ru unknown
- 2002-11-28 AT AT02785778T patent/ATE293982T1/de not_active IP Right Cessation
- 2002-11-28 MX MXPA04005506A patent/MXPA04005506A/es active IP Right Grant
- 2002-11-28 ES ES02785778T patent/ES2239728T3/es not_active Expired - Lifetime
- 2002-11-28 DE DE60203934T patent/DE60203934T2/de not_active Expired - Fee Related
- 2002-11-28 AP APAP/P/2004/003082A patent/AP2004003082A0/en unknown
- 2002-11-28 NZ NZ533054A patent/NZ533054A/en unknown
- 2002-11-28 AP APAP/P/2004/003053A patent/AP2004003053A0/en unknown
- 2002-11-28 OA OA1200400164A patent/OA12738A/en unknown
- 2002-11-28 DK DK02785778T patent/DK1455799T3/da active
- 2002-11-28 HU HU0402540A patent/HUP0402540A3/hu unknown
- 2002-11-28 KR KR1020047008609A patent/KR100685557B1/ko not_active Expired - Fee Related
- 2002-11-28 PL PL02370739A patent/PL370739A1/xx not_active Application Discontinuation
- 2002-11-28 PT PT02785778T patent/PT1455799E/pt unknown
- 2002-11-28 BR BR0214998-2A patent/BR0214998A/pt not_active IP Right Cessation
- 2002-11-28 CA CA002469085A patent/CA2469085A1/en not_active Abandoned
- 2002-11-29 TW TW091134818A patent/TWI256388B/zh not_active IP Right Cessation
- 2002-12-03 HN HN2002000348A patent/HN2002000348A/es unknown
- 2002-12-03 PE PE2002001164A patent/PE20030834A1/es not_active Application Discontinuation
- 2002-12-04 AR ARP020104685A patent/AR037634A1/es unknown
- 2002-12-05 SV SV2002001426A patent/SV2004001426A/es not_active Application Discontinuation
- 2002-12-05 GT GT200200258A patent/GT200200258A/es unknown
- 2002-12-05 UY UY27566A patent/UY27566A1/es not_active Application Discontinuation
- 2002-12-06 PA PA20028560701A patent/PA8560701A1/es unknown
-
2004
- 2004-05-21 IS IS7280A patent/IS7280A/is unknown
- 2004-05-21 ZA ZA200403966A patent/ZA200403966B/xx unknown
- 2004-06-02 MA MA27710A patent/MA27150A1/fr unknown
- 2004-06-03 CO CO04052108A patent/CO5580752A2/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005132A patent/ECSP045132A/es unknown
- 2004-06-04 TN TNP2004000101A patent/TNSN04101A1/fr unknown
- 2004-07-05 NO NO20042839A patent/NO20042839L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030289A1 (es) | Compuestos derivados de 2-aminocarbonil-9h-purina, su uso, proceso para su preparacion, composiciones farmaceuticas y compuestos intermediarios | |
| ES2527519T3 (es) | Compuestos de biciclilaril-aril-amina y su uso | |
| ES2904676T3 (es) | Compuestos de amino indol útiles como inhibidores de TLR | |
| ES2434467T3 (es) | Compuestos multicíclicos y métodos para su uso | |
| ES2705401T3 (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B | |
| AR037634A1 (es) | Combinacion farmaceutica, una composicion farmaceutica, uso de un agonista del receptor de adenosina a2a y dispositivo de inhalacion | |
| ES2398335T3 (es) | Compuestos de 4-piridinona y su uso para el cáncer | |
| ES2835729T3 (es) | Terapias de combinación para el tratamiento de cáncer | |
| ES2396135T3 (es) | Compuestos y composiciones como inhibidores de proteínas cinasas | |
| IL266894A (en) | (s)-4-(8-amino-3-(1-but-2-inoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridin-2- l) Benzamide as btk inhibitors | |
| CA2605854A1 (en) | Novel pyridine derivative and pyrimidine derivative (3) | |
| AR057104A1 (es) | Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica | |
| CA2665438C (en) | Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors | |
| EA200701245A1 (ru) | Производные 2,4(4,6)-пиримидинов | |
| KR20230090318A (ko) | 헬리오스의 피페리디닐 소분자 분해 및 사용 방법들 | |
| CZ285370B6 (cs) | Aminoheterocyklické deriváty jako antitrombotická a antikoagulační činidla | |
| HRP20120457T1 (hr) | 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba | |
| JP2012528137A5 (es) | ||
| CA2416274A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| CN103804371A (zh) | 化合物251 | |
| NO20065184L (no) | 1-amino-ftalazinderivater, deres fremstilling og terapeutiske anvendelse derav | |
| ES2903528T3 (es) | Compuestos de heteroarilo y su uso como inhibidores de MER | |
| MXPA05008584A (es) | Compuestos heterociclicos utiles como activadores de nurr-1. | |
| NZ512871A (en) | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | |
| JP2012521396A (ja) | ニコチンアミド誘導体、この調製および抗癌薬としてのこの治療的使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |